1. Biochemistry and Chemical Biology
  2. Structural Biology and Molecular Biophysics

Disease related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors

  1. Manoj K Rathinaswamy
  2. Zied Gaieb
  3. Kaelin D Fleming
  4. Chiara Borsari
  5. Noah J Harris
  6. Brandon J Moeller
  7. Matthias P Wymann
  8. Rommie E Amaro
  9. John E Burke  Is a corresponding author
  1. University of Victoria, Canada
  2. University of California, San Diego, United States
  3. University of Basel, Switzerland
https://doi.org/10.7554/eLife.64691
Share this article
Cite this article
  1. Manoj K Rathinaswamy
  2. Zied Gaieb
  3. Kaelin D Fleming
  4. Chiara Borsari
  5. Noah J Harris
  6. Brandon J Moeller
  7. Matthias P Wymann
  8. Rommie E Amaro
  9. John E Burke
(2021)
Disease related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors
eLife 10:e64691.
https://doi.org/10.7554/eLife.64691
  2. Download BibTeX
  3. Download .RIS

Abstract

Class I Phosphoinositide 3-kinases (PI3Ks) are master regulators of cellular functions, with the class IB PI3K catalytic subunit (p110g) playing key roles in immune signalling. p110g is a key factor in inflammatory diseases, and has been identified as a therapeutic target for cancers due to its immunomodulatory role. Using a combined biochemical/biophysical approach, we have revealed insight into regulation of kinase activity, specifically defining how immunodeficiency and oncogenic mutations of R1021 in the C-terminus can inactivate or activate enzyme activity. Screening of inhibitors using HDX-MS revealed that activation loop-binding inhibitors induce allosteric conformational changes that mimic those in the R1021C mutant. Structural analysis of advanced PI3K inhibitors in clinical development revealed novel binding pockets that can be exploited for further therapeutic development. Overall this work provides unique insights into regulatory mechanisms that control PI3Kg kinase activity, and shows a framework for the design of PI3K isoform and mutant selective inhibitors.

Data availability

The crystallography data has been deposited in the protein data bank with accession numbers (PDB: 7JWE, 7JX0, 7JWZ). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository[83] with the dataset identifier PXD021132. All data generated or analyzed during this study are included in the manuscript and supporting files. Specifically biochemical kinase assay data are included in the source data files.

The following previously published data sets were used

Article and author information

Author details

  1. Manoj K Rathinaswamy

    Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    Competing interests
    The authors declare that no competing interests exist.

  2. Zied Gaieb

    Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Kaelin D Fleming

    Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    Competing interests
    The authors declare that no competing interests exist.

  4. Chiara Borsari

    Department of Biomedicine, University of Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4688-8362

  5. Noah J Harris

    Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    Competing interests
    The authors declare that no competing interests exist.

  6. Brandon J Moeller

    Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    Competing interests
    The authors declare that no competing interests exist.

  7. Matthias P Wymann

    Department of Biomedicine, University of Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3349-4281

  8. Rommie E Amaro

    Chemistry and Biochemistry, National Biomedical Computation Resource, University of California, San Diego, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. John E Burke

    Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    For correspondence
    jeburke@uvic.ca
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7904-9859

Funding

Cancer Research Society (CRS-24368)

  • John E Burke

Michael Smith Foundation for Health Research (17686)

  • John E Burke

Canadian Institutes of Health Research (New Investigator)

  • John E Burke

National Institutes of Health (GM132826)

  • Zied Gaieb
  • Rommie E Amaro

Stiftung FHNW (341)

  • Matthias P Wymann

Swiss National Science (310030_189065)

  • Matthias P Wymann

Novartis Foundation (14B095)

  • Matthias P Wymann

Innosuisse - Schweizerische Agentur für Innovationsförderung (37213.1 IP-LS)

  • Matthias P Wymann

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Rathinaswamy et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,423
    views
  • 366
    downloads
  • 35
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Manoj K Rathinaswamy
  2. Zied Gaieb
  3. Kaelin D Fleming
  4. Chiara Borsari
  5. Noah J Harris
  6. Brandon J Moeller
  7. Matthias P Wymann
  8. Rommie E Amaro
  9. John E Burke
(2021)
Disease related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors
eLife 10:e64691.
https://doi.org/10.7554/eLife.64691

Share this article

https://doi.org/10.7554/eLife.64691

Categories and tags

Research organism

Further reading

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics

    High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery

    Conor J Howard, Nathan S Abell ... Nathan B Lubock
    Research Article

    Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.

    1. Biochemistry and Chemical Biology

    Coordinated regulation of chemotaxis and resistance to copper by CsoR in Pseudomonas putida

    Meina He, Yongxin Tao ... Wenli Chen
    Research Article

    Copper is an essential enzyme cofactor in bacteria, but excess copper is highly toxic. Bacteria can cope with copper stress by increasing copper resistance and initiating chemorepellent response. However, it remains unclear how bacteria coordinate chemotaxis and resistance to copper. By screening proteins that interacted with the chemotaxis kinase CheA, we identified a copper-binding repressor CsoR that interacted with CheA in Pseudomonas putida. CsoR interacted with the HPT (P1), Dimer (P3), and HATPase_c (P4) domains of CheA and inhibited CheA autophosphorylation, resulting in decreased chemotaxis. The copper-binding of CsoR weakened its interaction with CheA, which relieved the inhibition of chemotaxis by CsoR. In addition, CsoR bound to the promoter of copper-resistance genes to inhibit gene expression, and copper-binding released CsoR from the promoter, leading to increased gene expression and copper resistance. P. putida cells exhibited a chemorepellent response to copper in a CheA-dependent manner, and CsoR inhibited the chemorepellent response to copper. Besides, the CheA-CsoR interaction also existed in proteins from several other bacterial species. Our results revealed a mechanism by which bacteria coordinately regulated chemotaxis and resistance to copper by CsoR.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics

    Transcriptome-wide identification of 5-methylcytosine by deaminase and reader protein-assisted sequencing

    Jiale Zhou, Ding Zhao ... Zhanjun Li
    Research Article

    5-Methylcytosine (m5C) is one of the posttranscriptional modifications in mRNA and is involved in the pathogenesis of various diseases. However, the capacity of existing assays for accurately and comprehensively transcriptome-wide m5C mapping still needs improvement. Here, we develop a detection method named DRAM (deaminase and reader protein assisted RNA methylation analysis), in which deaminases (APOBEC1 and TadA-8e) are fused with m5C reader proteins (ALYREF and YBX1) to identify the m5C sites through deamination events neighboring the methylation sites. This antibody-free and bisulfite-free approach provides transcriptome-wide editing regions which are highly overlapped with the publicly available bisulfite-sequencing (BS-seq) datasets and allows for a more stable and comprehensive identification of the m5C loci. In addition, DRAM system even supports ultralow input RNA (10 ng). We anticipate that the DRAM system could pave the way for uncovering further biological functions of m5C modifications.